Analysis of gabapentin in serum and plasma by solid-phase extraction and gas chromatography - Mass spectrometry for therapeutic drug monitoring

Journal of Analytical Toxicology

Volumn 23, Issue 1, 1999, Pages 1-6

  Kushnir, M M ^a,b   Crossett, J ^b   Brown, P I ^b   Urry, F M ^b,c  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b ARUP LABORATORIES   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN;

ARTICLE; DRUG DETERMINATION; DRUG MONITORING; GAS CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; SOLID PHASE EXTRACTION; STATISTICAL ANALYSIS;

EID: 0032767799     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/23.1.1     Document Type: Article

References (16)

1. W.L. Olson, M. Gruenthal, M.E. Mueller, and W.H. Olson. Gabapentin for Parkinsonism: a double-blind, placebo-controlled, crossover trial. Am. J. Med. 102: 60-66 (1997).
2. C. Taylor. Emerging perspectives on the mechanism of action of gabapentin. Neurology 44: S10-16 (1994).
3. D. Chadwick. Drug profile: gabapentin. Lancet 343: 89-91 (1994).
4. E. Ben-Menachem, L.I. Persson, and T. Hedner. Selected CSF bio chemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose for gabapentin. Epilepsy Res. 11: 45-49 (1992).
5. L.L. Radulovic, D. Dietrich, A.V. Hodenberg, K.O. Vollmer, W.P. McNally, P.D. Dehart, B.J. Hanson, H.N. Bockbrader, and T. Chang. Disposition of gabapentin (Neurontin®) in mice, rats, dogs, and monkeys. Drug Metab. Dispos. 23: 441-448 (1995).
6. Physicians' Desk Reference. Medical Economics, Montvale, NJ, 1996, p 2879.
7. R. Ramsey. Clinical efficacy and safety of gabapentin. Neurology 44: S23-30 (1994).
8. J. Sivenius, R. Kalvianinen, A. Ylinin, and P. Riekkinin. Double blind study of gabapentin in the treatment of partial seizures. Epilepsia 32: 539-542 (1991).
9. K.L. Goa and E.M. Sorkin. Gabapentin. A review of its pharmacological and clinical potential in epilepsy. Drugs. 46: 409-427 (1993).
10. J. Goldberg and B. Green. Focus on gabapentin. Psychiatry On-Line. http//www.priory.com/focus8.htm, version 1.0 (1997).
11. H. Hengy and E.U. Kolle. Determination of gabapentin in plasma and urine by high performance liquid chromatography and pre-column labelling for ultraviolet detection. J. Chromatogr. 341: 473-478 (1985).
12. G.L. Lensmeyer, T. Kempf, B.A. Gatelle, and D.A. Wiebe. Optimized method for determination of gabapentin in serum by high-performance liquid chromatography. Ther. Drug. Monit. 17: 251-258 (1995).
13. W.D. Hooper, M.C. Kavanagh, and R.G. Dickinson. Determination of gabapentin in plasma and urine by capillary column gas chromatography. J. Chromatogr. 529: 167-174 (1990).
14. C.E. Wolf, II, J.J. Saady, and A. Poklis. Determination of gabapentin in serum using solid-phase extraction and gas-liquid chromatography. J. Anal. Toxicol. 20: 498-501 (1996).
15. P.J. Cornbleet and N. Gochman. Incorrect least-squares regression coefficients in method-comparison analysis. Clin. Chem. 25: 432-438 (1979).
16. G.V. Look, G. Simchen, and J. Heberle. Silylating Agents. Fluka Chemie AG, Buchs, Switzerland, 1995, p 199.